Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

311P - Differences in stromal component of chordoma are associated with contrast enhancement in MRI and differential gene expression in RNA sequencing

Date

10 Sep 2022

Session

Poster session 03

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Yoon Jin Cha

Citation

Annals of Oncology (2022) 33 (suppl_7): S122-S135. 10.1016/annonc/annonc1047

Authors

Y.J. Cha1, M. Park2, I. Park3, J.H. Kim4

Author affiliations

  • 1 Eonju-ro 211, Gangnam-gu, Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR
  • 2 Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR
  • 3 Precision Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR
  • 4 Medical Oncology Dept., Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 311P

Background

A recent study suggested that stroma percentage may have an important clinical impact on chordoma as it may be associated with tumor progression and treatment response. Considering that radiologic features, such as contrast enhancement and T2 signal intensity, are closely related with tumor component, we hypothesized that stroma and tumor cell component in chordomas may be associated with radiologic features visible on MRI and further associated with different histopathological features and genetic expressions. Therefore, we aimed to investigate whether chordomas with different stroma component show radiologic and genetic differences to obtain a better understanding of the heterogeneity of the disease.

Methods

A total of 45 patients diagnosed with chordoma were selected between May 2011 and March 2020 from a single institute. Electronic medical records, pathology slides, and pretreatment magnetic resonance imaging (MRI) scans were reviewed. Of the 45 patients, 10 (4 stroma-rich and 6 stroma-poor chordomas) were further analyzed using RNA sequencing. Differential gene expression and gene set analysis were performed.

Results

There were 25 (55.6%) stroma-rich and 20 (44.4%) stroma-poor chordomas. No clinical differences were found between the two groups. Radiologically, stroma-rich chordomas showed significant signal enhancement on MRI. Based on the results of RNA sequencing, the upregulated genes in stroma-rich chordomas were cartilage-, collagen/extracellular matrix-, and tumor metastasis/progression-associated genes. Contrarily, tumor suppressor genes were downregulated in stroma-rich chordomas.

Conclusions

In conclusion, the stromal component of chordoma differentially affects radiologic features and defines different genetic subgroups of chordoma. However, additional investigations with a larger cohort are needed to verify its clinical significance.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.